When will the CEO transition officially take place?

The CEO transition is scheduled to become effective on May 12, 2026 (the 'Transition Date').

What will be Jonathan (Jay) Mazelsky's role after stepping down as CEO?

Mr. Mazelsky will transition to the role of Executive Chair of the Board and will work closely with Dr. Erickson to ensure a seamless handover until his retirement in May 2027.

What is Dr. Michael Erickson's background and experience?

Dr. Erickson has been with IDEXX since 2011, holding senior positions in diagnostics, software, strategy, and corporate accounts. He currently serves as Executive Vice President and General Manager of IDEXX’s Global Point of Care Diagnostics and Telemedicine lines. Prior to IDEXX, he was an Associate Principal at McKinsey & Company, advising healthcare companies.

What are the key compensation elements for Dr. Erickson as the new CEO?

Dr. Erickson will receive an annualized base salary of $1,000,000, an annual bonus with a target of 120% of base salary, and is expected to receive a long-term incentive equity award with a target grant date value of at least $7.8 million for fiscal year 2026, composed of stock options and performance-based RSUs.

What are the severance provisions for Dr. Erickson if terminated without 'Cause' after the Transition Date?

If Dr. Erickson's employment is terminated by the Company without 'Cause' (and not under a change in control agreement), he is entitled to two years of salary continuation, employer-paid health benefits for two years, and continued vesting of equity awards for two years, subject to a release of claims and compliance with restrictive covenants.

IDXX 8-K: Leadership Changes & Regulation FD

Summary

IDEXX Laboratories, Inc. (IDXX) announced a CEO transition plan, with current President and CEO Jonathan (Jay) Mazelsky stepping down on May 12, 2026, and transitioning to the role of Executive Chair of the Board. He will retire in May 2027. Dr. Michael Erickson, currently Executive Vice President and General Manager of Global Point of Care Diagnostics and Telemedicine, will assume the roles of President and CEO and join the Board. Dr. Erickson has a strong background in healthcare technology and innovation, having been with IDEXX since 2011 and previously consulting with McKinsey & Company. This leadership change is designed to ensure a smooth handover and leverage Dr. Erickson's extensive experience within the company. The filing also details the compensation arrangements for both Mr. Mazelsky in his new role and Dr. Erickson as he takes on the CEO position. Dr. Erickson's compensation package includes a $1 million base salary, a target bonus of 120% of base salary, and a significant long-term incentive equity award valued at no less than $7.8 million for fiscal year 2026, comprising stock options and performance-based RSUs. Mr. Mazelsky will receive an annual base salary of $1,150,000 as Executive Chair, along with specific bonus and equity arrangements for fiscal year 2026. Both executives have entered into new agreements outlining terms for potential termination scenarios and change-in-control events, ensuring clarity and continuity.

Key Highlights

1Jonathan (Jay) Mazelsky to step down as CEO on May 12, 2026, transitioning to Executive Chair of the Board.
2Dr. Michael Erickson appointed as new President and CEO, effective May 12, 2026, and will join the Board.
3Dr. Erickson brings extensive experience in healthcare technology and innovation, with nearly two decades of leadership.
4Dr. Erickson's compensation package includes $1M base salary, 120% target bonus, and a minimum $7.8M in long-term equity for FY2026.
5Mr. Mazelsky to receive $1.15M base salary as Executive Chair, with defined bonus and equity for FY2026.
6Both executives have agreements detailing severance and change-in-control provisions.
7Lawrence D. Kingsley will serve as independent Lead Director.

IDEXX LABORATORIES INC /DE 8-K Report, Executive Changes (Jan 13, 2026)

Summary

Key Highlights

Frequently Asked Questions